$DNLI
Denali Therapeutics Inc. Stock $dnli

$dnli Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000171489923000049 Filed on February 27, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$35.14M	$10.28M	$108.5M
YoY Change	-16.61%	-17.83%	122.9%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$27.14M	$23.52M	$90.48M
YoY Change	20.4%	8.07%	14.44%
% of Gross Profit
Research & Development	$128.8M	$92.11M	$358.7M
YoY Change	49.62%	35.7%	35.19%
% of Gross Profit
Depreciation & Amortization	$10.05M	$4.091M	$10.40M
YoY Change	383.26%	95.37%	20.93%
% of Gross Profit
Operating Expenses	$156.0M	$115.6M	$449.2M
YoY Change	43.55%	29.0%	30.43%
Operating Profit	-$120.8M		-$340.7M
YoY Change	81.68%		15.21%
Interest Expense	$11.03M	$6.660M	$14.77M
YoY Change	763.38%	418.29%	221.52%
% of Operating Profit
Other Income/Expense, Net	$11.03M		$14.77M
YoY Change	763.38%		221.52%
Pretax Income	-$109.8M	-$98.68M	-$326.0M
YoY Change	68.32%	30.13%	11.96%
Income Tax		-$6.000K	$21.00K
% Of Pretax Income
Net Earnings	-$109.8M	-$98.68M	-$326.0M
YoY Change	68.32%	31.11%	12.19%
Net Earnings / Revenue	-312.4%	-959.62%	-300.56%
Basic Earnings Per Share	-$0.80		-$2.60
Diluted Earnings Per Share	-$0.80	-$0.74	-$2.60
COMMON SHARES
Basic Shares Outstanding	136.7M shares	135.8M shares	125.5M shares
Diluted Shares Outstanding	136.5M shares		125.5M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.288B	$1.336B	$1.336B
YoY Change	34.56%	54.4%	54.4%
Cash & Equivalents	$68.13M	$218.0M	$218.0M
Short-Term Investments	$1.220B	$1.118B	$1.118B
Other Short-Term Assets	$36.71M	$36.10M	$36.10M
YoY Change	18.75%	17.98%	17.98%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$1.325B	$1.372B	$1.372B
YoY Change	34.07%	52.95%	52.95%
LONG-TERM ASSETS
Property, Plant & Equipment	$42.12M	$44.09M	$74.52M
YoY Change	11.78%	13.44%	7.06%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Other Assets	$14.02M	$13.40M	$13.40M
YoY Change	-1.38%	12.87%	12.87%
Total Long-Term Assets	$84.18M	$87.92M	$87.92M
YoY Change	-74.68%	-82.66%	-82.66%
TOTAL ASSETS
Total Short-Term Assets	$1.325B	$1.372B	$1.372B
Total Long-Term Assets	$84.18M	$87.92M	$87.92M
Total Assets	$1.409B	$1.460B	$1.460B
YoY Change	6.7%	3.99%	3.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.215M	$2.790M	$2.790M
YoY Change	-34.04%	-41.62%	-41.62%
Accrued Expenses	$90.57M	$66.69M	$66.69M
YoY Change	103.34%	25.44%	25.44%
Deferred Revenue		$0.00
YoY Change		-100.0%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$391.1M	$363.9M	$363.9M
YoY Change	14.61%	-3.79%	-3.79%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$379.0K	$379.0K	$53.89M
YoY Change	0.0%	0.0%	-15.3%
Total Long-Term Liabilities	$379.0K	$379.0K	$53.89M
YoY Change	0.0%	0.0%	-15.3%
TOTAL LIABILITIES
Total Short-Term Liabilities	$391.1M	$363.9M	$363.9M
Total Long-Term Liabilities	$379.0K	$379.0K	$53.89M
Total Liabilities	$442.6M	$417.8M	$417.8M
YoY Change	9.85%	-5.44%	-5.44%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.081B	-$971.0M
YoY Change	52.17%	50.54%
Common Stock	$1.694M	$1.686M
YoY Change	9.01%	8.91%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$966.7M	$1.042B	$1.042B
YoY Change
Total Liabilities & Shareholders Equity	$1.409B	$1.460B	$1.460B
YoY Change	6.7%	3.99%	3.99%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$109.8M	-$98.68M	-$326.0M
YoY Change	68.32%	31.11%	12.19%
Depreciation, Depletion And Amortization	$10.05M	$4.091M	$10.40M
YoY Change	383.26%	95.37%	20.93%
Cash From Operating Activities	-$58.80M	-$72.66M	-$244.7M
YoY Change	-18.45%	10.95%	15.77%
INVESTING ACTIVITIES
Capital Expenditures	$2.786M	$4.849M	$17.83M
YoY Change	-31.06%	-258.83%	109.8%
Acquisitions
YoY Change
Other Investing Activities	-$89.93M	-$122.7M	-$123.6M
YoY Change	-21.0%	225.52%	841.29%
Cash From Investing Activities	-$92.72M	-$127.6M	-$141.4M
YoY Change	-21.35%	213.03%	553.78%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$296.2M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$1.604M	299.7M	$310.7M
YoY Change	9.64%	5698.2%	1505.7%
NET CHANGE
Cash From Operating Activities	-$58.80M	-72.66M	-$244.7M
Cash From Investing Activities	-$92.72M	-127.6M	-$141.4M
Cash From Financing Activities	$1.604M	299.7M	$310.7M
Net Change In Cash	-$149.9M	99.43M	-$75.43M
YoY Change	-20.48%	-198.37%	-64.7%
FREE CASH FLOW
Cash From Operating Activities	-$58.80M	-$72.66M	-$244.7M
Capital Expenditures	$2.786M	$4.849M	$17.83M
Free Cash Flow	-$61.59M	-$77.51M	-$262.5M
YoY Change	-19.12%	24.14%	19.4%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001714899
CY2021Q4	us-gaap	Derivative Liability Statement Of Financial Position Extensible Enumeration DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration	http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
CY2021Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-38311
CY2022	dei	Entity Registrant Name EntityRegistrantName	Denali Therapeutics Inc.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-3872213
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	161 Oyster Point Blvd
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	South San Francisco
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94080
CY2022	dei	City Area Code CityAreaCode	650
CY2022	dei	Local Phone Number LocalPhoneNumber	866-8548
CY2022	dei	Security12b Title Security12bTitle	Common Stock, par value $0.01 per share
CY2022	dei	Trading Symbol TradingSymbol	DNLI
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	false
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	1500000000	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	136677646	shares
CY2022	dei	Auditor Firm AuditorFirmId	42
CY2022	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2022	dei	Auditor Location AuditorLocation	San Mateo, California
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	218044000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	293477000	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	1118171000	usd
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	571930000	usd
CY2022Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	0	usd
CY2021Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	1226000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	36104000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	30601000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1372319000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	897234000	usd
CY2022Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	0	usd
CY2021Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	425449000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	44087000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	38865000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	30437000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	30743000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	13399000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	11871000	usd
CY2022Q4	us-gaap	Assets Assets	1460242000	usd
CY2021Q4	us-gaap	Assets Assets	1404162000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2790000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4779000	usd
CY2022Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	4388000	usd
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	0	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	66691000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	53165000	usd
CY2022Q4	dnli	Contract With Customer Liability From Related Parties Current ContractWithCustomerLiabilityFromRelatedPartiesCurrent	290053000	usd
CY2021Q4	dnli	Contract With Customer Liability From Related Parties Current ContractWithCustomerLiabilityFromRelatedPartiesCurrent	292386000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	27915000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	363922000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	378245000	usd
CY2022Q4	dnli	Contract With Customer Liability From Related Parties Noncurrent ContractWithCustomerLiabilityFromRelatedPartiesNoncurrent	479000	usd
CY2021Q4	dnli	Contract With Customer Liability From Related Parties Noncurrent ContractWithCustomerLiabilityFromRelatedPartiesNoncurrent	1295000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	0	usd
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	3398000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	53032000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	58554000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	379000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	379000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	417812000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	441871000	usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	40000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	40000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	135965918	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	135965918	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	122283305	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	122283305	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1686000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	1548000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2018617000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1608238000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-6886000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2499000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-970987000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-644996000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1042430000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	962291000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1460242000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1404162000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	105065000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	48657000	usd
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	335561000	usd
CY2022	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	3398000	usd
CY2021	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	4000	usd
CY2020	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	98000	usd
CY2022	us-gaap	Revenues Revenues	108463000	usd
CY2021	us-gaap	Revenues Revenues	48661000	usd
CY2020	us-gaap	Revenues Revenues	335659000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	358732000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	265353000	usd
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	212615000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	90475000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	79059000	usd
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	60326000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	449207000	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	344412000	usd
CY2020	us-gaap	Operating Expenses OperatingExpenses	272941000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-340744000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-295751000	usd
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	62718000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	14774000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4595000	usd
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	9241000	usd
CY2022	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-325970000	usd
CY2021	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-291156000	usd
CY2020	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	71959000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	21000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-575000	usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	823000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-325991000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-290581000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	71136000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-4387000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-2254000	usd
CY2020	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-595000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-330378000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-292835000	usd
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	70541000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.60
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.39
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.65
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.60
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.39
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.63
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	125530703	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	121524795	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	108974137	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	125530703	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	121524795	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	112703108	shares
CY2022	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	3200000	usd
CY2021	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	3700000	usd
CY2020	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	307400000	usd
CY2022	dnli	Due To Related Parties Expense Current DueToRelatedPartiesExpenseCurrent	8200000	usd
CY2021	dnli	Research And Development Expense Offset From Related Party Cost Reimbursement ResearchAndDevelopmentExpenseOffsetFromRelatedPartyCostReimbursement	6500000	usd
CY2020	dnli	Research And Development Expense Offset From Related Party Cost Reimbursement ResearchAndDevelopmentExpenseOffsetFromRelatedPartyCostReimbursement	9300000	usd
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	394890000	usd
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	193948000	usd
CY2020	dnli	Stock Issued During Period Value Stock Purchase Agreement StockIssuedDuringPeriodValueStockPurchaseAgreement	420146000	usd
CY2020	dnli	Stock Issued During Period Value Equity Incentive Plan StockIssuedDuringPeriodValueEquityIncentivePlan	20655000	usd
CY2020	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	50351000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	71136000	usd
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-595000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1150531000	usd
CY2021	dnli	Stock Issued During Period Value Equity Incentive Plan StockIssuedDuringPeriodValueEquityIncentivePlan	19348000	usd
CY2021	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	85247000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-290581000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-2254000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	962291000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	296215000	usd
CY2022	dnli	Stock Issued During Period Value Equity Incentive Plan StockIssuedDuringPeriodValueEquityIncentivePlan	14455000	usd
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	99847000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-325991000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-4387000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1042430000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-325991000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-290581000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	71136000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	10383000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	8593000	usd
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	8531000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	99847000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	85247000	usd
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	50351000	usd
CY2022	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	1637000	usd
CY2021	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-8748000	usd
CY2020	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-55000	usd
CY2022	dnli	Increase Decrease In Non Cash Operating Lease Expense IncreaseDecreaseInNonCashOperatingLeaseExpense	3351000	usd
CY2021	dnli	Increase Decrease In Non Cash Operating Lease Expense IncreaseDecreaseInNonCashOperatingLeaseExpense	2984000	usd
CY2020	dnli	Increase Decrease In Non Cash Operating Lease Expense IncreaseDecreaseInNonCashOperatingLeaseExpense	2360000	usd
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-63000	usd
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	usd
CY2020	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-38000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2760000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	12865000	usd
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	10569000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2274000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3705000	usd
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1623000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	10918000	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	4732000	usd
CY2020	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	22106000	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-31313000	usd
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-11925000	usd
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-19253000	usd
CY2022	dnli	Increase Decrease In Contract With Customer Liability Related Parties IncreaseDecreaseInContractWithCustomerLiabilityRelatedParties	-3149000	usd
CY2021	dnli	Increase Decrease In Contract With Customer Liability Related Parties IncreaseDecreaseInContractWithCustomerLiabilityRelatedParties	-3737000	usd
CY2020	dnli	Increase Decrease In Contract With Customer Liability Related Parties IncreaseDecreaseInContractWithCustomerLiabilityRelatedParties	297418000	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	0	usd
CY2021	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-322000	usd
CY2020	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	322000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-244716000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-211389000	usd
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	416152000	usd
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	1115040000	usd
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	1422938000	usd
CY2020	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	1285468000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	17833000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8500000	usd
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3095000	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	991486000	usd
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	1409812000	usd
CY2020	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	665357000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-141387000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-21626000	usd
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-623206000	usd
CY2022	dnli	Proceeds From Issuance Of Common Stock In Connection With Collaboration Agreement ProceedsFromIssuanceOfCommonStockInConnectionWithCollaborationAgreement	0	usd
CY2021	dnli	Proceeds From Issuance Of Common Stock In Connection With Collaboration Agreement ProceedsFromIssuanceOfCommonStockInConnectionWithCollaborationAgreement	0	usd
CY2020	dnli	Proceeds From Issuance Of Common Stock In Connection With Collaboration Agreement ProceedsFromIssuanceOfCommonStockInConnectionWithCollaborationAgreement	420146000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	296215000	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	193948000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	14455000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	19348000	usd
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	20655000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	310670000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	19348000	usd
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	634749000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-75433000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-213667000	usd
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	427695000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	294977000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	508644000	usd
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	80949000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	219544000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	294977000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	508644000	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	47000	usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	210000	usd
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2022	dnli	Issuance Costs Incurred But Not Yet Paid IssuanceCostsIncurredButNotYetPaid	224000	usd
CY2021	dnli	Issuance Costs Incurred But Not Yet Paid IssuanceCostsIncurredButNotYetPaid	0	usd
CY2020	dnli	Issuance Costs Incurred But Not Yet Paid IssuanceCostsIncurredButNotYetPaid	0	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1464000	usd
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	593000	usd
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	67000	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported amounts of expenses during the reporting period. Actual results could differ from those estimates, and such differences could be material to the Consolidated Balance Sheets and Consolidated Statements of Operations and Comprehensive Income (Loss).</span></div>
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and marketable securities. Substantially all of the Company’s cash and cash equivalents are deposited in accounts with financial institutions that management believes are of high credit quality. Such deposits have and will continue to exceed federally insured limits. The Company maintains its cash with accredited financial institutions and accordingly, such funds are subject to minimal credit risk. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s investment policy limits investments to certain types of securities issued by the U.S. government and its agencies, as well as institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and marketable securities and issuers of marketable securities to the extent recorded on the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Balance Sheets</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As of December 31, 2022 and 2021, the Company had no off-balance sheet concentrations of credit risk.</span></div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to a number of risks similar to other clinical-stage biopharmaceutical companies, including, but not limited to, the need to obtain adequate additional funding, possible failure of current or future preclinical testing or clinical trials, its reliance on third parties to conduct its clinical trials, the need to obtain regulatory and marketing approvals for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company’s product candidates, its right to develop and commercialize its product candidates pursuant to the terms and conditions of the licenses granted to the Company, protection of proprietary technology, the ability to make milestone, royalty or other payments due under any license or collaboration agreements, and the need to secure and maintain adequate manufacturing arrangements with third parties. If the Company does not successfully commercialize or partner any of its product candidates, it will be unable to generate product revenue or achieve profitability. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the company is also subject to broad market risks and uncertainties resulting from recent events, such as the COVID-19 pandemic, the Russian invasion of Ukraine, inflation, rising interest rates, and recession risks as well as supply chain and labor shortages.</span>
CY2022Q4	dnli	Concentration Risk Credit Risk Financial Instruments Off Balance Sheet Risk Amount ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRiskAmount	0	usd
CY2021Q4	dnli	Concentration Risk Credit Risk Financial Instruments Off Balance Sheet Risk Amount ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRiskAmount	0	usd
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	40000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1500000	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	1277240000	usd
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	1262673000	usd
CY2021Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	111000	usd
CY2021Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	111000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	1124718000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	96000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	6643000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1118171000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	999527000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2149000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	997379000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Term DebtSecuritiesAvailableForSaleTerm	P1Y
CY2022	us-gaap	Revenues Revenues	108463000	usd
CY2021	us-gaap	Revenues Revenues	48661000	usd
CY2020	us-gaap	Revenues Revenues	335659000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	81302000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	68209000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	37215000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	29344000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	44087000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	38865000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	10400000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	8600000	usd
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	8500000	usd
CY2022Q4	dnli	Other Accrued Manufacturing Costs OtherAccruedManufacturingCosts	22307000	usd
CY2021Q4	dnli	Other Accrued Manufacturing Costs OtherAccruedManufacturingCosts	9955000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	17087000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	19013000	usd
CY2022Q4	dnli	Accrued Clinical And Other Accrued Research And Development Costs AccruedClinicalAndOtherAccruedResearchAndDevelopmentCosts	16297000	usd
CY2021Q4	dnli	Accrued Clinical And Other Accrued Research And Development Costs AccruedClinicalAndOtherAccruedResearchAndDevelopmentCosts	15887000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	7318000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5453000	usd
CY2022Q4	dnli	Other Accrued Costs And Other Liabilities Current OtherAccruedCostsAndOtherLiabilitiesCurrent	3682000	usd
CY2021Q4	dnli	Other Accrued Costs And Other Liabilities Current OtherAccruedCostsAndOtherLiabilitiesCurrent	2857000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	66691000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	53165000	usd
CY2022	us-gaap	Lease Cost LeaseCost	12200000	usd
CY2021	us-gaap	Lease Cost LeaseCost	11200000	usd
CY2020	us-gaap	Lease Cost LeaseCost	11100000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	11189000	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	10336000	usd
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	9737000	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y2M12D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y3M18D
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y3M18D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.089
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.09
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.09
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	12237000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	12122000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	11793000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	12182000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	12584000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	17382000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	78300000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	17950000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	60350000	usd
CY2022	us-gaap	Sublease Income SubleaseIncome	3900000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	12600000	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	47900000	usd
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	43800000	usd
CY2021	us-gaap	Sublease Income SubleaseIncome	3800000	usd
CY2020	us-gaap	Sublease Income SubleaseIncome	3600000	usd
CY2022Q4	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	3096000	usd
CY2022Q4	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	876000	usd
CY2022Q4	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	3972000	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	13686386	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	24.33
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y9M3D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	333011000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2255840	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	43.06
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	720904	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	14.59
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	547605	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	41.82
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	14673717	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	27.03
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y2M26D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	127865000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	13083022	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	30.24
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y8M1D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	84709000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	9886659	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	21.71
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P5Y7M28D
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	101574000	usd
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	23.96
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	11.83
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	11.51
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	26
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	41.3
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	15.67
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	99847000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	85247000	usd
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	50351000	usd
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	197600000	usd
CY2022	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y6M
CY2021	dnli	Share Based Payment Arrangement Vest Or Exercise Of Option Tax Benefit ShareBasedPaymentArrangementVestOrExerciseOfOptionTaxBenefit	0	usd
CY2022	dnli	Share Based Payment Arrangement Vest Or Exercise Of Option Tax Benefit ShareBasedPaymentArrangementVestOrExerciseOfOptionTaxBenefit	0	usd
CY2020	dnli	Share Based Payment Arrangement Vest Or Exercise Of Option Tax Benefit ShareBasedPaymentArrangementVestOrExerciseOfOptionTaxBenefit	1000000	usd
CY2022	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0	usd
CY2021	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0	usd
CY2020	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0	usd
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	2800000	usd
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	2300000	usd
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1900000	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	7000	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-576000	usd
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	823000	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	14000	usd
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	1000	usd
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	21000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-575000	usd
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	823000	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.011
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.251
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.282
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.040
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.049
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.041
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.092
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.005
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0.032
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.079
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.004
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.001
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.001
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.001
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.002
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.011
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	67492000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	59285000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	69562000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	48058000	usd
CY2022Q4	dnli	Deferred Tax Assets Research Expense Capitalization DeferredTaxAssetsResearchExpenseCapitalization	61869000	usd
CY2021Q4	dnli	Deferred Tax Assets Research Expense Capitalization DeferredTaxAssetsResearchExpenseCapitalization	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	70824000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	75281000	usd
CY2022Q4	dnli	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	14712000	usd
CY2021Q4	dnli	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	15040000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	44473000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	30185000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	18381000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	15385000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	347313000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	243234000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	332580000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	228586000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	14733000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	14648000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	7314000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	7424000	usd
CY2022Q4	dnli	Deferred Tax Liabilities Operating Lease Right Of Use Asset DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset	7419000	usd
CY2021Q4	dnli	Deferred Tax Liabilities Operating Lease Right Of Use Asset DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset	7224000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2022Q4	dnli	Deferred Tax Assets Research Expense Capitalization DeferredTaxAssetsResearchExpenseCapitalization	61900000	usd
CY2021Q4	dnli	Deferred Tax Assets Valuation Allowance Percent DeferredTaxAssetsValuationAllowancePercent	1
CY2022Q4	dnli	Deferred Tax Assets Valuation Allowance Percent DeferredTaxAssetsValuationAllowancePercent	1
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	104000000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	13699000	usd
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	8139000	usd
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5299000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	135000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	1042000	usd
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	5537000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	4725000	usd
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	3009000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	207000	usd
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	169000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	19371000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	13699000	usd
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	8139000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2022Q4	us-gaap	Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Amount Of Unrecorded Benefit SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit	0	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-325991000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-290581000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	71136000	usd
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	125530703	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	121524795	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	108974137	shares
CY2022	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2021	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2020	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	3728971	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	125530703	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	121524795	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	112703108	shares
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.60
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.39
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.65
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.60
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.39
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.63
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	18200000	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16500000	shares
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4200000	shares

Files In Submission

Name	View Source	Status
0001714899-23-000049-index-headers.html	Edgar Link	pending
0001714899-23-000049-index.html	Edgar Link	pending
0001714899-23-000049.txt	Edgar Link	pending
0001714899-23-000049-xbrl.zip	Edgar Link	pending
amendmentno7todevelopmenta.htm	Edgar Link	pending
amendmentno8todevelopmenta.htm	Edgar Link	pending
amendmentno9todevelopmenta.htm	Edgar Link	pending
dnli-20221231.htm	Edgar Link	pending
dnli-20221231.xsd	Edgar Link	pending
dnli-20221231_g1.jpg	Edgar Link	pending
dnli-20221231_g10.jpg	Edgar Link	pending
dnli-20221231_g11.jpg	Edgar Link	pending
dnli-20221231_g12.jpg	Edgar Link	pending
dnli-20221231_g13.jpg	Edgar Link	pending
dnli-20221231_g14.jpg	Edgar Link	pending
dnli-20221231_g15.jpg	Edgar Link	pending
dnli-20221231_g16.jpg	Edgar Link	pending
dnli-20221231_g2.jpg	Edgar Link	pending
dnli-20221231_g3.jpg	Edgar Link	pending
dnli-20221231_g4.jpg	Edgar Link	pending
dnli-20221231_g5.jpg	Edgar Link	pending
dnli-20221231_g6.jpg	Edgar Link	pending
dnli-20221231_g7.jpg	Edgar Link	pending
dnli-20221231_g8.jpg	Edgar Link	pending
dnli-20221231_g9.jpg	Edgar Link	pending
exhibit211q42022subsidiari.htm	Edgar Link	pending
exhibit231q42022.htm	Edgar Link	pending
exhibit311q42022.htm	Edgar Link	pending
exhibit312q42022.htm	Edgar Link	pending
exhibit321q42022.htm	Edgar Link	pending
exhibit322q42022.htm	Edgar Link	pending
exhibit44q42022description.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
dnli-20221231_def.xml	Edgar Link	unprocessable
dnli-20221231_htm.xml	Edgar Link	completed
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
dnli-20221231_cal.xml	Edgar Link	unprocessable
dnli-20221231_pre.xml	Edgar Link	unprocessable
dnli-20221231_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DNLI
Denali Therapeutics Inc. Stock $dnli

2023 Q1 Form 10-K Financial Statement

#000171489923000049 Filed on February 27, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DNLI Denali Therapeutics Inc. Stock $dnli

2023 Q1 Form 10-K Financial Statement

#000171489923000049 Filed on February 27, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DNLI
Denali Therapeutics Inc. Stock $dnli